Investors Purchase High Volume of Replimune Group Call Options (NASDAQ:REPL)

Key Points

• Replimune Group experienced a significant surge in options trading, with traders purchasing 32,634 call options, marking a 614% increase from the average daily volume.
• CEO Sushil Patel sold 25,105 shares of the company's stock at an average price of $8.06, reducing his ownership by 6.81%.
• Several institutional investors, including TD Asset Management and Goldman Sachs, increased their stakes in Replimune Group, with institutional ownership now standing at 92.53% of the company.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) saw unusually large options trading on Wednesday. Stock traders bought 32,634 call options on the company. Thisrepresentsanincreaseof614% compared to the average volume of 4,571 call options.

Replimune Group Trading Up 3.1%

Shares of Replimune Group stock traded up $0.22 during midday trading on Friday, reaching $7.25. 3,805,165 shares of the company's stock traded hands, compared to its average volume of 3,867,073. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95. The company has a market cap of $564.12 million, a PE ratio of -2.34 and a beta of 0.61. The stock has a 50 day moving average of $9.05 and a 200-day moving average of $10.11. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the prior year, the company posted ($0.25) earnings per share. As a group, equities analysts expect that Replimune Group will post -2.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on REPL shares. Piper Sandler downgraded shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 target price for the company. in a research note on Tuesday, July 22nd. Jefferies Financial Group reduced their target price on Replimune Group from $31.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. HC Wainwright lowered Replimune Group from a "buy" rating to a "neutral" rating in a report on Wednesday, July 23rd. Leerink Partnrs lowered Replimune Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 22nd. Finally, Wedbush reaffirmed a "neutral" rating and set a $4.00 target price (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Replimune Group has a consensus rating of "Hold" and an average target price of $7.67.

Insider Activity at Replimune Group

In other news, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $260,168.74. Following the sale, the director directly owned 1,405,071 shares in the company, valued at $11,324,872.26. The trade was a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the sale, the insider owned 128,296 shares in the company, valued at $1,032,782.80. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after acquiring an additional 1,655 shares during the last quarter. US Bancorp DE grew its stake in shares of Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock worth $45,000 after acquiring an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after acquiring an additional 5,922 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Replimune Group by 99.9% during the second quarter. AlphaQuest LLC now owns 9,857 shares of the company's stock valued at $92,000 after buying an additional 4,925 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd boosted its position in shares of Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.